相关实验视频

Updated: Jun 11, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

在活性氧物种分层的质母细胞瘤中,EZH2功能二分法

Lynnette Wei Hsien Koh¹, Qing You Pang¹, Wisna Novera¹

¹Neuro-Oncology Research Laboratory, Department of Research, National Neuroscience Institute, Singapore, Singapore.

|October 7, 2024

概括

增强质同源2 (EZH2) 在质母细胞瘤 (GBM) 亚型中具有双重作用. 用一个NIK抑制剂准其非正规功能显示出治疗耐化学性瘤的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

增强质同源2 (EZH2) 在像质母细胞瘤 (GBM) 这样的癌症中的转录抑制中起着关键作用.
EZH2已经研究了对瘤生长至关重要的非正规功能,特别是在GBM分子异质性的背景下.
目前针对其正规甲基转移酶活性的EZH2抑制剂的疗效有限,需要探索替代治疗策略.

研究的目的:

为了研究EZH2CXC域在不同,反应性氧物种 (ROS) 分层的GBM瘤中的双重作用.
在GBM亚型中确定与EZH2非正规功能相关的治疗漏洞.
探索针对EZH2的非甲基转移酶活动的新型治疗方法,用于抗化学性GBM.

主要方法:

在ROS类之间进行基因表达差异分析,以确定EZH2作为关键介质.
利用拉下测试和CRISPR-Cas9技术在GBM细胞中剖析EZH2域功能.
评估了NF-κB诱导激酶抑制剂 (NIKinh) 和temozolomide在患者衍生的GBM异种移植中的疗效.

主要成果:

在ROS阳性瘤中,EZH2的CXC域与RelB相互作用,激活非正规NF-κB2信号,并赋予化学抵抗.
在ROS阴性亚型中,EZH2的正规甲基转移酶活性抑制NF-κB信号传递.
一种穿透大脑的NIK抑制剂破坏了EZH2-RelB结合,显著延长了ROS阳性GBM异种移植中的存活时间.

结论:

在GBM中,EZH2 CXC域在调节ROS分层治疗耐药性方面表现出功能二分法.
针对EZH2的非正规活动,而不是其甲基转移酶功能,提供了一个有前途的治疗途径.
基于ROS水平的患者分层对于开发有效的,针对性治疗GBM至关重要.

关键词:

在 EZH2 中使用.大脑癌症大脑癌症质母细胞瘤 (glioblastoma) 是一种患者分层是患者的分层.精准医学是一门精准医学.

更多相关视频

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...